Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Reprocell Inc.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Deals Business Strategies

Regenerative Medicine Policy In Japan Could Serve As Global Breeding Ground For New Technologies

Japan’s evolving policy on regenerative medicine approval and safety could create a gateway for global market entry.

BioPharmaceutical Japan

Regenerative Medicine Policy In Japan Could Serve As Global Breeding Ground For New Technologies

Japan’s evolving policy on regenerative medicine approval and safety could create a gateway for global market entry.

BioPharmaceutical Japan

Deals Shaping The Medical Industry, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • Distributors
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register